QIBA/NIBIB Round-2 Project #22a

2-month Interim Report

Project aim: validate PERCIST metrics using peer-reviewed patient cohorts.

Methods
1. re-analysis of PET datasets available at Vumc, in non-small cell lung cancer treated with systemic therapy using the PERCIST metrics
2. comparison with the original methodology used in the publications, and vs their reference tests (pathology or survival)

Outcomes/deliverables
1. accuracy of PERCIST vs conventional PET quantitative approaches, and robustness in context of different systemic treatment modalities
2. teaching module

Interim status per June 30st 2012:
Mid-April – End June
Completed image re-analysis of bevacizumab/erlotinib and sorafenib/erlotinib

Further planning:
End June-end August: image re-analysis Cisplatinum and erlotinib datasets
September: statistical analyses & reporting.
Delivery of full project foreseen Oct 1st.